See more : NextPlat Corp (NXPL) Income Statement Analysis – Financial Results
Complete financial analysis of Goodbody Health Limited (GDBYF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Goodbody Health Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Clear Sky Lithium Corp. (CSKYF) Income Statement Analysis – Financial Results
- Prosperity Investment Holdings Limited (0310.HK) Income Statement Analysis – Financial Results
- AGES Industri AB (publ) (AGES-B.ST) Income Statement Analysis – Financial Results
- Jigar Cables Limited (JIGAR.BO) Income Statement Analysis – Financial Results
- TienPin United Enterprise CO., LTD. (6199.TWO) Income Statement Analysis – Financial Results
Goodbody Health Limited (GDBYF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.goodbodyhealth.com
About Goodbody Health Limited
Goodbody Health Inc., a wellness company, provides health and wellness range of products and services in the United Kingdom. The company also operates as a vertically integrated cannabinoid (CBD) company that operates in the United Kingdom and the European Union. It has interests in COVID and blood testing clinics, CBD extraction, wholesale bulk isolate and distillate sales, retail CBD and white label sales, cannabinoid laboratory testing, and medicinal cannabis research programs. The company was formerly known as Sativa Wellness Group Inc. and changed its name to Goodbody Health Inc. in January 2022. The company is headquartered in Vancouver, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.06M | 1.99M | 1.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.13M | 870.53K | 695.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.93M | 1.12M | 754.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 52.36% | 56.35% | 52.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.27M | 4.74M | 3.53M | 175.40K | 14.06K | 40.11K | 46.03K | 46.19K | 40.30K | 42.42K |
| Selling & Marketing | 4.22M | 539.98K | 471.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.48M | 5.28M | 4.00M | 175.40K | 14.06K | 40.11K | 46.03K | 46.19K | 40.30K | 42.42K |
| Other Expenses | 446.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.93M | 5.77M | 4.31M | 175.40K | 14.06K | 42.82K | 148.62K | 52.45K | 40.30K | 42.42K |
| Cost & Expenses | 17.06M | 6.64M | 5.00M | 175.40K | 14.06K | 42.82K | 148.62K | 52.45K | 40.30K | 42.42K |
| Interest Income | 0.00 | 63.54K | 0.00 | 0.00 | 0.00 | 2.48K | 0.00 | 2.61K | 3.82K | 964.53 |
| Interest Expense | 0.00 | 27.02K | 0.00 | 1.27K | 77.53 | 0.00 | 0.00 | 0.00 | 40.12 | 56.55 |
| Depreciation & Amortization | 1.04M | 471.39K | 259.54K | 493.77 | 161.48K | 22.82K | 30.69K | 0.00 | 3.82K | 1.02K |
| EBITDA | -13.74K | -4.12M | -3.29M | -175.40K | 147.35K | -42.82K | -118.04K | -52.45K | -36.48K | -41.45K |
| EBITDA Ratio | -0.08% | -200.32% | -211.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 321.62K | -4.47M | -3.32M | -175.90K | -14.13K | -42.82K | -148.73K | -52.45K | -40.30K | -42.47K |
| Operating Income Ratio | 1.89% | -223.96% | -229.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.57M | -195.69K | -477.72K | -625.84K | -161.33K | 2.42K | -30.58K | 2.57K | 3.78K | 964.53 |
| Income Before Tax | -2.25M | -4.79M | -3.80M | -348.81K | -175.46K | -40.40K | -179.20K | -49.87K | -36.52K | -41.51K |
| Income Before Tax Ratio | -13.17% | -240.04% | -261.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 67.63K | -128.17K | 244.56K | 780.68 | -77.53 | -22.82K | -112.82 | 0.00 | 0.00 | 0.00 |
| Net Income | -2.31M | -4.66M | -3.80M | -348.81K | -175.46K | -40.40K | -179.20K | -49.87K | -36.52K | -41.51K |
| Net Income Ratio | -13.57% | -233.61% | -261.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.07 | -0.29 | -0.48 | -0.17 | -0.18 | -0.08 | -0.35 | -0.16 | -0.12 | -0.52 |
| EPS Diluted | -0.07 | -0.29 | -0.48 | -0.17 | -0.18 | -0.08 | -0.35 | -0.16 | -0.12 | -0.52 |
| Weighted Avg Shares Out | 34.62M | 16.25M | 7.96M | 2.01M | 975.18K | 525.55K | 509.81K | 315.80K | 315.80K | 79.38K |
| Weighted Avg Shares Out (Dil) | 34.62M | 16.25M | 7.96M | 2.01M | 975.18K | 525.55K | 509.81K | 315.80K | 315.80K | 79.38K |
Goodbody Health makes strategic strides
Goodbody Health Ltd (AQSE:GDBY) said its 2022 results reflect its successful diversification as it added a wider range of diagnostic tests and began to provide minor procedures. It reported turnover of over £10mln for the year ending December 31 -...
Goodbody Health launches mobile blood testing service
Goodbody Health has launched its new mobile phlebotomy service to “develop and increase” the reach of phlebotomy testing. Phlebotomy is a procedure whereby blood is taken from a vein via a needle for laboratory testing.
Goodbody Health extends phlebotomy services with contract win
Goodbody Health signed a contract with blood testing company Thriva as it continues to make progress on extending its phlebotomy services. A phlebotomy is when blood is taken from your body via a needle.
Goodbody Health to offer multi-cancer screening services via liquid biopsy test
Goodbody Health Ltd (AQSE:GDBY, OTCQB:GDBYF) said its network of UK clinics will start offering multi-cancer screening service, as part of a partnership agreed with a liquid biopsy specialist. Datar Cancer Genetics, a liquid biopsy company headquartered in India, offers multi-cancer...
Goodbody Health reports boardroom changes
Goodbody Health Ltd (AQSE:GDBY, OTCQB:GDBYF) has announced that its chair Geremy Thomas will be stepping down from his executive duties, effective 1st January 2023. Thomas will remain with the company as non-executive chair.
Goodbody Health sells Polish CBD facility
Goodbody Health has agreed to sell its Polish CBD-related operations to Voyager Life for £1.5mln, comprising £0.5m cash and £1mln of convertible loan notes. The divestment comprises the share sale of Sativa Wellness Poland and Olimax, subsidiaries that combined provide...
Goodbody Health announces appointment of George Thomas as its chief executive officer with immediate effect
Goodbody Health Ltd (AQSE:GDBY, OTCQB:GDBYF) has announced that George Thomas, an existing executive director of the company and managing director of Goodbody Wellness has been appointed as the company's chief executive officer with immediate effect. The company said Thomas replaces Marc Howells...
Goodbody Health turns focus to preventative diagnostics
Goodbody Health Ltd (AQSE:GDBY, OTCQB:GDBYF) said its focus is now on preventative diagnostics as it looks to become a “leading aggregator” of innovative technology and tests. The health diagnostics firm said in a third-quarter trading update that it will focus...
Never a better time to be proactive about cancer testing, says Goodbody Health
Goodbody Health Ltd (AQSE:GDBY, OTCQB:GDBYF) chief executive Marc Howells has urged Britons to better understand their potential hereditary cancer risks. Howells, reacting to reports that a former UK cancer tsar described the NHS screening as a ‘late diagnosis service' and...
Goodbody Health inks deal to offer its suite of services in Allied Pharmacies outlets
Goodbody Health Ltd (AQSE:GDBY, OTCQB:GDBYF) said it will offer a range of diagnostic services and earwax micro-suction at 17 outlets owned by the Allied Pharmacies chain. Earwax removal is no longer offered by most GPs, so patients are increasingly turning...
Source: https://incomestatements.info
Category: Stock Reports